For years, clinicians have relied on established categories such as monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), and active multiple myeloma (MM) to assess disease risk and guide patient management. But emerging research suggests that these classifications may not fully capture the biological complexity of myeloma precursor disease.
Advances in genomics, immune profiling, and single-cell technologies are revealing that patients with seemingly similar clinical presentations may have very different underlying disease biology—and very different risks of progression.
These evolving insights will be explored by Francesco Maura, MD, during his session, “Mapping Early Myeloma: Molecular and Biological Drivers from MGUS to Smoldering Disease,” at LL&M Congress.
Looking Beyond Traditional Disease Categories
Historically, MGUS and SMM have been defined using clinical criteria, including M-protein levels, bone marrow plasma cell burden, and evidence of end-organ damage. While these classifications remain clinically useful, researchers are increasingly discovering that precursor disease may be far more biologically diverse than previously appreciated.
Recent genomic studies suggest that some patients classified as smoldering myeloma show no evidence of malignant transformation, while others harbor molecular features usually seen in multiple myeloma.
As a result, investigators are beginning to ask whether future disease classification should incorporate biology alongside clinical criteria.
Faculty Perspective
"The most surprising finding was that SMM and MGUS can be genomically similar to multiple myeloma, yet remain stable for more than five years."
Understanding What Drives Progression
One of the most important questions in myeloma research remains: why do some patients progress while others remain stable for years?
To answer this question, researchers are increasingly looking beyond the tumor itself.
Studies examining precursor disease have identified immune changes that may occur before clinical progression, including alterations in T-cell populations and inflammatory signaling pathways. At the same time, single-cell analyses of the bone marrow microenvironment have revealed changes in stromal and bone-forming cell populations that appear to evolve alongside disease development.
Together, these findings suggest that progression from MGUS to active myeloma involves complex interactions between malignant plasma cells, the immune system, and the bone marrow niche.
During his LL&M Congress session, Dr. Maura will review emerging evidence surrounding these molecular and biological drivers of progression and discuss how they may influence future approaches to risk assessment and patient monitoring.
A Shift Toward Dynamic Risk Assessment
Risk stratification has traditionally relied on baseline clinical measurements collected at a single point in time. However, researchers are increasingly recognizing that disease biology is dynamic.
Newer models are incorporating longitudinal changes in laboratory and clinical parameters to better identify patients who are progressing biologically, even before overt clinical symptoms develop.
This evolving approach reflects a broader shift within the field—from categorizing risk based solely on where a patient is today to understanding where their disease may be heading tomorrow.
As these tools continue to mature, they may help clinicians personalize surveillance strategies and identify patients who could benefit from earlier intervention.
Why This Research Matters Now
The rapid pace of discovery in myeloma research is generating new insights across multiple areas of disease biology.
Recent work from Dr. Maura and colleagues, including findings from the Polyethnic-1000 initiative, has highlighted how large-scale genomic studies can challenge longstanding assumptions about multiple myeloma development and outcomes. These studies suggest that understanding disease biology requires looking beyond tumor genomics alone and considering the broader biological and clinical context.
Collectively, these advances are contributing to a more comprehensive view of myeloma progression—one that integrates genomic evolution, immune remodeling, microenvironmental changes, and patient-specific factors.
Faculty Perspective
"We believe that genomics can refine the historical MGUS and SMM classification by defining three entities: 1) indolent or benign plasma-cell clonal expansions with no risk of progression to MM and no evidence of malignant transformation; 2) genomic myeloma, in which an already transformed clone remains stable for years under immune-system control; and 3) genomic myeloma that escapes immune control and expands, ultimately causing organ damage."
Looking Ahead
As our understanding of precursor disease continues to evolve, so too does the opportunity to improve patient care.
By integrating genomic alterations, immune signatures, bone marrow microenvironment changes, and dynamic monitoring strategies, researchers are building a more nuanced understanding of disease progression. These advances may ultimately help clinicians identify high-risk patients earlier, refine monitoring approaches, and better personalize treatment decisions.
Join Dr. Francesco Maura at LL&M Congress this October 13-16 as he explores the latest discoveries shaping our understanding of myeloma precursor disease and what they may mean for the future of risk stratification, disease interception, and patient management.